drugset / Trial / NCT02576314
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of Sofosbuvir containing regimens in treatment-naive or treatment-experienced patients with HCV genotype 3 infection.
Timeline
- Start
- 2015-05
- Primary completion
- 2017-12-31
- Completion
- 2018-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Daclatasvir | Small molecule | 60 mg | Oral |
| Comparator | Ledipasvir/sofosbuvir | Unknown | 90 mg | Oral |
| Comparator | Ledipasvir/sofosbuvir | Unknown | 400 mg | Oral |
| Comparator | Sofosbuvir | Small molecule | 400 mg | Oral |